Literature DB >> 32934006

Fluorescence assay for simultaneous quantification of CFTR ion-channel function and plasma membrane proximity.

Stella Prins1, Emily Langron1, Cato Hastings2, Emily J Hill1, Andra C Stefan3, Lewis D Griffin2, Paola Vergani4.   

Abstract

The cystic fibrosis transmembrane conductance regulator (CFTR) is a plasma membrane anion channel that plays a key role in controlling transepithelial fluid movement. Excessive activation results in intestinal fluid loss during secretory diarrheas, whereas CFTR mutations underlie cystic fibrosis (CF). Anion permeability depends both on how well CFTR channels work (permeation/gating) and on how many are present at the membrane. Recently, treatments with two drug classes targeting CFTR-one boosting ion-channel function (potentiators) and the other increasing plasma membrane density (correctors)-have provided significant health benefits to CF patients. Here, we present an image-based fluorescence assay that can rapidly and simultaneously estimate both CFTR ion-channel function and the protein's proximity to the membrane. We monitor F508del-CFTR, the most common CF-causing variant, and confirm rescue by low temperature, CFTR-targeting drugs and second-site revertant mutation R1070W. In addition, we characterize a panel of 62 CF-causing mutations. Our measurements correlate well with published data (electrophysiology and biochemistry), further confirming validity of the assay. Finally, we profile effects of acute treatment with approved potentiator drug VX-770 on the rare-mutation panel. Mapping the potentiation profile on CFTR structures raises mechanistic hypotheses on drug action, suggesting that VX-770 might allow an open-channel conformation with an alternative arrangement of domain interfaces. The assay is a valuable tool for investigation of CFTR molecular mechanisms, allowing accurate inferences on gating/permeation. In addition, by providing a two-dimensional characterization of the CFTR protein, it could better inform development of single-drug and precision therapies addressing the root cause of CF disease.
© 2020 Prins et al.

Entities:  

Keywords:  ABC transporter; VX-770; anion transport; conductance; cystic fibrosis; cystic fibrosis transmembrane conductance regulator (CFTR); fluorescence; gating; intracellular trafficking; microscopic imaging; molecular pharmacology; protein stability

Mesh:

Substances:

Year:  2020        PMID: 32934006      PMCID: PMC7864054          DOI: 10.1074/jbc.RA120.014061

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  94 in total

1.  Conformational Changes of CFTR upon Phosphorylation and ATP Binding.

Authors:  Zhe Zhang; Fangyu Liu; Jue Chen
Journal:  Cell       Date:  2017-07-20       Impact factor: 41.582

2.  Triple CFTR Modulator Therapy for Cystic Fibrosis.

Authors:  Fernando Holguin
Journal:  N Engl J Med       Date:  2018-10-18       Impact factor: 91.245

3.  Molecular Structure of the Human CFTR Ion Channel.

Authors:  Fangyu Liu; Zhe Zhang; László Csanády; David C Gadsby; Jue Chen
Journal:  Cell       Date:  2017-03-23       Impact factor: 41.582

4.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

Authors:  J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

5.  Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.

Authors:  J P Clancy; Steven M Rowe; Frank J Accurso; Moira L Aitken; Raouf S Amin; Melissa A Ashlock; Manfred Ballmann; Michael P Boyle; Inez Bronsveld; Preston W Campbell; Kris De Boeck; Scott H Donaldson; Henry L Dorkin; Jordan M Dunitz; Peter R Durie; Manu Jain; Anissa Leonard; Karen S McCoy; Richard B Moss; Joseph M Pilewski; Daniel B Rosenbluth; Ronald C Rubenstein; Michael S Schechter; Martyn Botfield; Claudia L Ordoñez; George T Spencer-Green; Laurent Vernillet; Steve Wisseh; Karl Yen; Michael W Konstan
Journal:  Thorax       Date:  2011-08-08       Impact factor: 9.139

6.  Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

Authors:  Claire E Wainwright; J Stuart Elborn; Bonnie W Ramsey; Gautham Marigowda; Xiaohong Huang; Marco Cipolli; Carla Colombo; Jane C Davies; Kris De Boeck; Patrick A Flume; Michael W Konstan; Susanna A McColley; Karen McCoy; Edward F McKone; Anne Munck; Felix Ratjen; Steven M Rowe; David Waltz; Michael P Boyle
Journal:  N Engl J Med       Date:  2015-05-17       Impact factor: 91.245

7.  Novel adenoviral vectors coding for GFP-tagged wtCFTR and deltaF508-CFTR: characterization of expression and electrophysiological properties in A549 cells.

Authors:  Horia Vais; Guang-Ping Gao; Michael Yang; Phoi Tran; Jean-Pierre Louboutin; Suryanarayan Somanathan; James M Wilson; William W Reenstra
Journal:  Pflugers Arch       Date:  2004-12       Impact factor: 3.657

8.  Residual function of cystic fibrosis mutants predicts response to small molecule CFTR modulators.

Authors:  Sangwoo T Han; Andras Rab; Matthew J Pellicore; Emily F Davis; Allison F McCague; Taylor A Evans; Anya T Joynt; Zhongzhou Lu; Zhiwei Cai; Karen S Raraigh; Jeong S Hong; David N Sheppard; Eric J Sorscher; Garry R Cutting
Journal:  JCI Insight       Date:  2018-07-26

9.  Phenylglycine and sulfonamide correctors of defective delta F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating.

Authors:  Nicoletta Pedemonte; N D Sonawane; Alessandro Taddei; Jie Hu; Olga Zegarra-Moran; Yat Fan Suen; Lori I Robins; Christopher W Dicus; Dan Willenbring; Michael H Nantz; Mark J Kurth; Luis J V Galietta; A S Verkman
Journal:  Mol Pharmacol       Date:  2005-02-18       Impact factor: 4.436

10.  Protein traffic disorders: an effective high-throughput fluorescence microscopy pipeline for drug discovery.

Authors:  Hugo M Botelho; Inna Uliyakina; Nikhil T Awatade; Maria C Proença; Christian Tischer; Lalida Sirianant; Karl Kunzelmann; Rainer Pepperkok; Margarida D Amaral
Journal:  Sci Rep       Date:  2015-03-12       Impact factor: 4.379

View more
  2 in total

Review 1.  Assays of CFTR Function In Vitro, Ex Vivo and In Vivo.

Authors:  Anabela Santo Ramalho; Mieke Boon; Marijke Proesmans; François Vermeulen; Marianne S Carlon; Kris De Boeck
Journal:  Int J Mol Sci       Date:  2022-01-27       Impact factor: 5.923

Review 2.  Strategies for cystic fibrosis transmembrane conductance regulator inhibition: from molecular mechanisms to treatment for secretory diarrhoeas.

Authors:  Hugo R de Jonge; Maria C Ardelean; Marcel J C Bijvelds; Paola Vergani
Journal:  FEBS Lett       Date:  2020-11-16       Impact factor: 3.864

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.